Ribocure Pharmaceuticals AB
Ribocure Pharmaceuticals AB is a Swedish clinical stage biotech company focused on developing innovative RNA-based therapeutics, particularly for cardiovascular, liver, and kidney diseases. The company collaborates with global partners such as Boehringer Ingelheim and Ribo Life Science to advance treatments for liver diseases, rare diseases, and other unmet medical needs. With a strong emphasis on clinical trials, research, and regulatory strategies, Ribocure aims to transform liver disease treatment and address high unmet patient needs worldwide.
Industries
Nr. of Employees
small (1-50)
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11, Floor 5, SE-431 53 Mölndal, Sweden
Products
Liver‑targeted siRNA candidate targeting Factor XI (antithrombotic)
Conjugated liver‑directed siRNA therapeutic candidate designed to silence coagulation Factor XI for antithrombotic indications; progressed into clinical evaluation.
Liver‑targeted siRNA candidate targeting APOC3 (lipid lowering)
Liver‑directed siRNA program targeting APOC3 to reduce triglycerides; authorized for clinical evaluation in mixed dyslipidemia.
Liver‑targeted siRNA programs for chronic hepatitis B / D
siRNA programs targeting chronic viral hepatitis indications with granted patents and progressed clinical evaluations.
Liver‑targeted siRNA candidate targeting Factor XI (antithrombotic)
Conjugated liver‑directed siRNA therapeutic candidate designed to silence coagulation Factor XI for antithrombotic indications; progressed into clinical evaluation.
Liver‑targeted siRNA candidate targeting APOC3 (lipid lowering)
Liver‑directed siRNA program targeting APOC3 to reduce triglycerides; authorized for clinical evaluation in mixed dyslipidemia.
Liver‑targeted siRNA programs for chronic hepatitis B / D
siRNA programs targeting chronic viral hepatitis indications with granted patents and progressed clinical evaluations.
Services
Execution of early‑phase clinical studies including recruitment, dosing, safety monitoring, advanced endpoints and overnight in‑clinic assessments.
AI and data‑driven services to integrate multi‑omic datasets for target profiling, prioritization and patient stratification strategies.
In‑house in vitro human cell assays and in vivo models for target validation, pharmacology and proof‑of‑concept studies to support candidate selection and regulatory filings.
Co‑development and managed partnerships with external industry partners to advance preclinical siRNA programs and achieve program milestones.
Operational integration with primary care health centers to broaden trial access and recruit more representative patient populations outside hospital settings.
Execution of early‑phase clinical studies including recruitment, dosing, safety monitoring, advanced endpoints and overnight in‑clinic assessments.
AI and data‑driven services to integrate multi‑omic datasets for target profiling, prioritization and patient stratification strategies.
In‑house in vitro human cell assays and in vivo models for target validation, pharmacology and proof‑of‑concept studies to support candidate selection and regulatory filings.
Co‑development and managed partnerships with external industry partners to advance preclinical siRNA programs and achieve program milestones.
Operational integration with primary care health centers to broaden trial access and recruit more representative patient populations outside hospital settings.
Expertise Areas
- Oligonucleotide therapeutics (siRNA)
- Early‑phase clinical trial management (Phase I–II)
- Deep phenotyping and biomarker discovery
- AI‑assisted multi‑omic target discovery and analytics
Key Technologies
- siRNA therapeutics
- Conjugated liver‑targeting delivery (GalNAc‑type)
- Oligonucleotide chemistry and synthesis
- AI‑driven multi‑omic analytics
News & Updates
Suzhou Ribo Life Science and Ribocure AB announced a key pre-clinical milestone in their siRNA programs, validating the Ribo platform and organization, and advancing treatments for liver diseases.
Ribocure Pharmaceuticals AB announced EMA approval to start a Phase II clinical trial evaluating the efficacy and safety of RBD1016 for chronic hepatitis D infection.
Ribo announced patent approvals in the US and Europe for RBD1016, strengthening its intellectual property portfolio for HBV treatment.
The Phase 1 trial for RBD4059, targeting coagulation factor XI, was completed, evaluating safety, tolerability, and pharmacokinetics.
Ribocure announced EMA authorization to proceed with a Phase II trial for RBD1016 targeting chronic hepatitis D.
Suzhou Ribo Life Science and Ribocure AB announced a key pre-clinical milestone in their siRNA programs, validating the Ribo platform and organization, and advancing treatments for liver diseases.
Ribocure Pharmaceuticals AB announced EMA approval to start a Phase II clinical trial evaluating the efficacy and safety of RBD1016 for chronic hepatitis D infection.
Ribo announced patent approvals in the US and Europe for RBD1016, strengthening its intellectual property portfolio for HBV treatment.
The Phase 1 trial for RBD4059, targeting coagulation factor XI, was completed, evaluating safety, tolerability, and pharmacokinetics.
Ribocure announced EMA authorization to proceed with a Phase II trial for RBD1016 targeting chronic hepatitis D.